Preliminary studies involving the use of a formulation comprising a mixture of powdered fruit bodies of several wild medicinal East African mushrooms in the treatment of patients with Kaposi's sarcoma (an opportunistic skin cancer aff ecting patients affl icted with HIV/AIDS) show promising therapeutic results. Th e same product has also benefi ted patients with HIV/AIDS.
Th e product, GACOCA, has been used in Tanzania since 2001. Initially it was used to treat patients with HIV/AIDS in Ifakara Morogoro in central Tanzania under the supervision of Dr. Henry Moshi of St. Francis Hospital, who found that patients achieved noticeable improvement in health. Later, trials in Dare s-Salaam on patients with Kaposi's sarcoma revealed encouraging responses with complete resolution of the condition in a fraction of these patients. GACOCA has also demonstrated promising eff ectiveness in other conditions including diabetes, high blood pressure, libido problems, and bedwetting. Th ese encouraging medicinal values of the GACOCA mushroom warrant further evaluation in properly designed clinical trials.
GACOCA contains several mushrooms of established medicinal value, which are abundantly available in the East African woodlands. I list them below according to their botanical names.
• Ganoderma species include G. lucidum (W. • Trametes versicolor (L.:Fr.) Lloyd (=Coriolus versicolor) (Turkey tail) has immune enhancement, antitumor, antiviral, antibacterial, and antioxidant properties. PSK, a derivative of this mushroom, is an approved anticancer drug in Asia. Th e drug is popularly used in the treatment of stomach cancer, among others. Another form of extract, PSP, is an antiviral agent inhibiting HIV replication based on in vitro studies. Th is is probably the most well-documented medicinal mushroom according to authorities in medicinal mushrooms.
• Cantharellus species include C. Th e mushroom species described above have been identifi ed in large quantities in Tanzania and East Africa, and we are working with hospital clinicians, natural therapists, and traditional healers to study their medicinal value in our settings. It is my intention to make this information available so that the GACOCA mushroom will interest scientists, medical professionals, environmentalists, the business community, educators, and any other stakeholders in the region and the world. I believe there is big potential here, especially now when pollution is already a concern elsewhere in the world.
I was introduced to this mushroom back in 1967. At that time I was staying in Sigulu Island on lake Victoria, Uganda, with my grandmother Veronica Ajiambo, who adopted me after the death of my father in 1963 at Jipe, Mwanga in Kilimanjaro, Tanzania. She taught me the art of identifying and picking mushrooms.
In 1980 I learned about mushroom cultivation. In 1993 I started collecting mushroom literature from the best world authorities. I read all I could about mushrooms, cultivated them, collected them, identifi ed them, and worked with local consultants to design clinical trials.
Today in Tanzania the GACOCA mushroom is being used as an immune booster by patients with HIV + , Kaposi's sarcoma, and arthritis, among other illnesses. Th rough HBCPs (home based care providers) the GACOCA mushroom is distributed to the community in the Kibaha coast region. I work with KIDEFO (Kibaha Development Foundation) to support the community healthwise. We intend to expand the service countrywide, and expect to make GACOCA extracts in early 2005. Th e center for production of this mushroom is in Kibaha Maili moja coast region in Tanzania. It is collected from diff erent regions in the country and processed for community. Some is sold to pharmaceutical shops and supermarkets to sustain the GACOCA project. 
